Abstract: The present invention is generally related to an oral disinfectant for companion animals. A preferred disinfectant is a concentrated composition containing a fatty acid monoester, one or more fatty acids, an acid or chelating agent, a polyalcohol, a surfactant and water. When used the concentrate is diluted with water and then applied to the teeth and oral cavity tissues of the animal.

Abstract: The present invention discloses a method for removing iodine compounds from acetic acid, in which the iodine compound is removed by using a solid adsorbent in the form of an activated carbon fiber having a large strength, a large bulk density, and a large specific surface, so that the treatment of large amounts should be possible, that the acetic acid should not be contaminated during the extraction of foreign materials from the adsorbent, and that the adsorbent can be repeatedly used by regenerating it. The method includes the steps of: preparing a filter in the usual manner by using an activated carbon fiber as the adsorbent; and making acetic acid containing an iodide pass through the activated carbon fiber filter, whereby the iodide in acetic acid is removed by being adsorbed by the activated carbon fiber filter.

Abstract: A cleaning fluid for fabrics includes one or more hydrochlorofluorocarbons and/or hydrofluorocarbons, one or more alcohols and/or glycol ethers, and one or more paraffinic hydrocarbons.

Abstract: Non-aqueous compositions for topical application comprising one or more active ingredients and a fatty alkoxylate ester emollient agent comprising a diester or triester of an aliphatic or aromatic tricarboxylic acid formed by reacting the acid with a stoichiometric excess of one or more polyalkoxylated fatty alcohols.

Abstract: The present invention relates to compositions and methods for preventing pneumococcal infection. In particular, the invention relates to identification of the major reception for Streptococcus pneumoniae on activated human cells, and diagnostic and therapeutic compositions and methods based thereon. In particular, the invention relates to the discovery that platelet activating factor (PAF) receptor is an adhesive ligand for pneumococcal adherence to activated lung epithelial and venous endothelial (i.e., host) cells. Accordingly, the present invention is directed to a method for preventing or treating an infection with Streptococcus pneumoniae by administering an antagonist of platelet activating factor receptor. The invention further relates to recognition that adherence to activated cells also involves a carbohydrate ligand found on such activated cells.

Abstract: A method of producing perfluorocarbon halides in a one-pot reaction is described. The method employs a perfluorocarbon acid, a first halogenating agent and a second halogen which drives the reaction forward. Novel perfluorocarbon halides and a direct method for producing perfluorocarbon hypohalites also are described.

Abstract: A process for preparing adipic acid from cyclohexene oxide comprising the following steps (a) and (b):(a) hydrating cyclohexene oxide to obtain 1,2-dihydroxycyclohexane and an oligomers represented by formula (I): ##STR1## wherein n represents a number of from 1 to 5 in number average, and (b) oxidizing the 1,2-dihydroxycyclohexane and the oligomers represented by formula (I) in a nitric acid aqueous solution.

Abstract: Perhydro-5,5-8a-trimethyl-2-naphthalenone is prepared by acid cyclization of carboxylic esters of formula ##STR1## having a double bond in one of the positions indicated by the dotted lines and wherein symbol R designates a C.sub.1 -C.sub.6 alkyl radical, X stands for a monovalent radical of formula P(O)(OR.sup.1).sub.2 or C(O)R.sup.2, R.sup.1 represents a C.sub.1 -C.sub.6 alkyl group and R.sup.2 is either a linear or branched alkyl group or a substituted or unsubstituted phenyl radical, and wherein the wavy line represents a C--C bond of cis or trans configuration, or of formula ##STR2## wherein the wavy lines and symbol R are defined as above, and R.sup.0 represents a C.sub.3 -C.sub.6 alkyl radical, preferably branched, followed by basic decarboxylation of the obtained product.

Abstract: An influenza virus neuraminidase inhibitor, its analogs, its pharmaceutically acceptable salts, derivatives, and mixtures thereof having the following formula: ##STR1## where A is CO.sub.2 H, CO.sub.2 H.sub.3, NO.sub.2, SO.sub.3 H or PO.sub.3 H.sub.2, B is CH, N, O or S, R.sub.1 and R.sub.2 are H, NO.sub.2 or (CH.sub.m).sub.n X.sub.1 where m=1 or 2, n is an integer from 0 to 4 and X.sub.1 is guanidino, OH, NH.sub.2, SH, NO.sub.2, F, Cl, Br, I, CN, CF.sub.3, CO.sub.2 H, SO.sub.3 H or PO.sub.3 H.sub.2, R.sub.3 and R.sub.4 are H, (CH.sub.o).sub.p X.sub.2, (CH.sub.o).sub.p CHX.sub.2 CH.sub.2 X.sub.2, NH(CH.sub.o).sub.p CHX.sub.2 CH.sub.2 X.sub.2, NHCO(CH.sub.o).sub.p CH.sub.2 X.sub.2 or NHCO(CH.sub.o).sub.p CHX.sub.2 CH.sub.2 X.sub.2 where o=1 or 2, p is an integer from 0 to 4 and X.sub.2 is H, guanidino, OH, NH.sub.2, SH, NO.sub.2, CF.sub.3, CO.sub.2 H, SO.sub.3 H or PO.sub.3 H.sub.2 , R.sub.5 =H, OH, NH.sub.2, (CH.sub.k).sub.1 X.sub.3, CO(CH.sub.k).sub.1 X.sub.3, SO(CH.sub.k).sub.1 X.sub.3 or SO.sub.2 (CH.sub.

Abstract: A process for the manufacture of aromatic dicarboxylic acids is disclosed using a low bromine to metals ratio facilitated by the use of cerium along with the cobalt and manganese catalyst. Aromatic dicarboxylic acids such as terephthalic acid are useful in the manufacture of fiber, films, bottles and molded products.

Abstract: Polycarbamates of a polyisocyanate and secondary alcohols are disclosed. These carbamates are characterized in being readily pyrolyzed to form the corresponding polyisocyanate and alcohol with low formation of tars and other by-products. Thus, these polycarbamates can be pyrolyzed under relatively mild conditions, and in the absence of solvent and catalyst.

Abstract: Methods and pharmaceutical compositions for reducing the biological fluid level of a lipid soluble waste in a subject are provided. The methods involve selecting a subject diagnosed as having a hyperlipidemia-associated condition and subcutaneously introducing into the subject a biodegradable implant containing a pro-inflammatory lipid that promotes formation of an angiogenic tissue capsule containing a plurality of foam cells. The pro-inflammatory lipid is delivered in an amount sufficient to attain a detectable reduction in the biological fluid level of the lipid soluble waste.

Abstract: Absorbable composite materials are described that comprise a collagen matrix reinforced with a layer of a bioabsorbable polymer. A chemotherapeutic agent is dispersed in the composite material. The layer of bioabsorbable polymer is preferably a woven, nonwoven or knitted mesh layer of a synthetic bioabsorbable polymer such as polylactic/polyglycolic acid copolymer, or oxidised regenerated cellulose. The chemotherapeutic agent may be an antibiotic, an anaesthetic, an antiseptic or an anti-inflammatory. Strips of the composite material are inserted into the periodontal pocket, where they are retained in place and provide effective sustained release of the chemotherapeutic agent over an extended period.

Abstract: Disclosed herein are methods directed generally to the control of neural activity and to the treatment of neural disorders. More particularly, the present invention is directed to methods for the modification of mammalian neural activity through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative and neurological disorders.

Abstract: The present invention provides methods for lowering serum cholesterol comprising administering to a mammal in need of treatment a serum cholesterol lowering amount of a compound of formula I or formula II ##STR1## wherein L is --CON< or --N<; andthe dotted line in the B-ring is an optional bond; or a pharmaceutically acceptable salt thereof; and ##STR2## wherein Q is a moiety having the formula ##STR3## L is --CON< or --N<; B is --O--, --S--, --CH.sub.2 -phenyl-O--, -phenyl-O--, or -benzyl-O--;G is a moiety which together with L forms a substituted or unsubstituted heterocyclic ring having at least one nitrogen atom or is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (C.sub.3 -C.sub.7)cycloalkyl, halo(lower)alkyl, cyano(lower)alkyl, carboxy(lower)alkyl, (lower)alkoxycarbonyl(lower)alkyl, (C.sub.6 -C.sub.10)aryl, (C.sub.7 -C.sub.11)aryl akyl, di(lower)alkylamino(lower)alkyl, and fluoro-substituted analogs of the foregoing;Z is --O--, --S--, --CH.sub.

Abstract: A novel skin lotion consisting of a mixture of lye, oils, alcohol, coal tar, and menthol U.S.P. The mixture provides a cleansing lotion that readily treats psoriasis. When the mixture is applied to the skin, the lye provides a soap for cleansing and the base oil operates to soften and moisturize the skin. The use of a coal tar solution including alcohol penetrates the dermis of the skin to reduce inflammation. The addition of menthol U.S.P. helps cool the affected area and lessens itching.

Abstract: A synthetic fibers having a melting or softening temperature of 160.degree. C. or more, for example, polyester fibers, are dyed with an organic coloring material having a molecular weight of 370 or more, for example, disperse dye, vat dye and phthalocyanine pigment, at a temperature of 150.degree. C. or more, at a high color depth, and the resultant dyed product exhibits a high color fastness to washing or light.

Abstract: A pharmaceutical preparation and method for the treatment of diseases due to defects in the immune system using cystine derivatives.

Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. These small molecules are useful for treating vasoconstrictive, inflammatory, myeloid suppressive, cardiovascular, and gastrointestinal diseases.

Abstract: The present invention provides certain novel 4-phenylpinene derivatives, and teaches how to use said novel derivatives and related compounds in pharmaceutical compositions that have utility in treating various pathological conditions associated with damage to the central nervous system. The active ingredient of the pharmaceutical compositions according to the present invention is a compound of the formula: ##STR1## wherein A - - - B designates an optional double bond, R.sub.1 designates a variety of organic moieties, G designates alkyl, halogen, or various oxy groups, and R.sub.3 designates various alkyl groups, ether groups, or combinations thereof.